HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant Builds Outside Of Dermatology With Bausch + Lomb Buy

This article was originally published in The Rose Sheet

Executive Summary

Acquisition of Bausch + Lomb for $8.7 billion vaults Valeant Pharmaceuticals into consumer eye care and positions the firm to compete against pharma giants. Analysts see the move as representing “a good fit,” and the acquisition is not likely to be the last for Valeant, which has made M&A an integral part of its strategy.

You may also be interested in...

US HBW Executive Decisions: Bausch + Lomb CMO, GOED Expands Staff

Yehia Hashad joins Bausch + Lomb as R&D executive VP and chief medical officer before a planned IPO; Global Organization for EPA and DHA Omega-3s begins 2022 creating a position of growth and engagement director and adding two team members.

J&J Rides Standalone Consumer Health Track

J&J takes same approach GSK, Pfizer, Merck & Co, Merck and Novartis have with their consumer health businesses, Bausch Health is starting and Sanofi says it will.

In Brief

FDA invites public input in preparation for the seventh meeting of national authorities under the International Cooperation on Cosmetics Regulation, while The National Toxicology Program requests information on technologies and non-animal approaches that can be used to screen compounds for potential neurotoxicity. More news in brief.

Related Content

Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts